Skip to main content

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

Active, not recruiting · NCT04632953

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

At a glance

Research payments reported, 2025
$599,732
U.S. investigators named
13
Sites paid
13
Planned or actual enrollment
150

About the trial

Sponsor
Ultragenyx Pharmaceutical Inc
Tested
No Intervention (other)
Dates
Started 2021-11-30; completion 2035-12
Results posted
Not yet

The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.

From ClinicalTrials.gov, last updated 2026-06-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ultragenyx Pharmaceutical Inc. reported $599,732 in research payments for this study in 2025 (108 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.